Asia Pacific Smart Inhalers Market Research Report - Segmented By Product Type, By Disorder, By End-user and By Country (India, China, Japan, Australia, New Zealand, ASEAN Countries and Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2024 to 2029)

Updated On: January, 2024
ID: 5829
Pages: 145

Asia Pacific Smart Inhalers Market Size (2023 to 2028)

The size of the Smart Inhalers Market in the Asia Pacific was worth USD 25.71 million in 2023 and is estimated to be growing at a CAGR of 75.23% to reach USD 424.70 million by 2028. 

The growth of the APAC smart inhalers market is primarily due to an increasing elderly population, an increased prevalence of chronic obstructive pulmonary disease and asthma, and increased medical awareness.

The growth of the smart inhaler market is due to increased air pollution and the burden on healthcare services due to the increased number of cases of COPD and asthma. Besides, more smart inhalers are being used to properly manage COPD and asthma, further driving the market growth. In addition, the rapid development of urbanization and an increase in the number of people with respiratory diseases are increasing throughout the Asia-Pacific region.

Some of the other factors that have led to an increase in the number of cases of asthma and COPD throughout the Asia-Pacific region are increased air pollution levels and increased smoking habits. In addition, an increasing number of patients with asthma and chronic obstructive pulmonary disease and technological advances in developing better smart inhalers and systems present growth opportunities for the market. Also, developing regions with large populations and the potential of untapped markets are expected to provide ample opportunities for trends in the Asia-Pacific smart inhalers market. 

The dearth of skilled persons is a major challenging factor in the APAC Smart Inhalers Market. In addition, fluctuations in the availability of raw materials used to manufacture smart inhalers are limiting the market's growth.

This research report on the APAC smart inhalers market has been segmented and sub-segmented into the following categories:

By Product Type: 

  • Nebulizers
  • Inhalers

By Disorder: 

  • Chronic Obstructive Pulmonary Disease
  • Asthma
  • Others

By End-user: 

  • Patients
  • R&D
  • Others

By Country: 

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Regionally, the Asia-Pacific region is anticipated to have the fastest-growing rate due to the high investments by government organizations and private companies in the medical industry, growth in the aging population, and emerging economies like China and India.

India and China are the two major countries contributing to the significant support to the growth of the APAC market. Increasing the economy steadily from the past few years is ascribed to bolster the market demand in these countries. Besides, growing awareness among people towards the availability of various products also greatly influences the demand of the smart inhalers market. Moreover, the rising need to launch innovative products in favor of the end-users is extensively boosting up the growth rate of this market.

The Japanese smart inhalers market is predicted to perform well during the forecast period due to the growing number of respiratory diseases, the emergence of technological advancements, and the rising scale of research centers in the medical sector.

The Australian smart inhalers market is deemed to have a steady pace during the forecast period. The rise in the prevalence to provide better healthcare infrastructure and facilities to the patients is lucrative to set up growth opportunities for the market in these countries.


A few of the prominent companies operating in the APAC Smart Inhalers Market profiled in this report are Vectura Group plc, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Boehringer Ingelheim GmbH, AstraZeneca plc, Adherium Limited, Cohero Health, LLC, Propeller Health, GlaxoSmithKline plc and OPKO Health, Inc.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample